Clinically, a combination of an ICI (atezolizumab, anti-PD-L1 mAb) with antiangiogenic therapy (bevacizumab, anti-vascular endothelial growth factor (VEGF) mAb) has led to major breakthroughs in treatment of metastatic NSCLC and renal cell carcinoma (RCC) 117, 118. Here, CD274 is linked to renal cell carcinoma.